<b>Mass, Residency Duration, and Previous Experience Shape Post-Escalation but Not Pre-Escalation Outcomes in Experimental Territorial Contests of Atlantic Mudskippers (</b><b><i>P... by Michael Smith (21714377)

DataSheet1_Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR... by Colton Ladbury (19768281)

Deep reinforcement learning agents trained using a curriculum solve navigation tasks with delayed rewards. by William L. Tong (22238845)

Functional characterization of skinned myocardium prepared from Epac1TG. by Yoshiki Ohnuki (576298)

Effects of chronic ISO infusion on cardiac function in Epac1TG. by Yoshiki Ohnuki (576298)

R scripts. by Ehsan Ghafouri (21688451)

“…<div><p>Climate change has emerged as a significant driver of biodiversity loss, with profound implications for species distribution. …”

Bioclimatic variables used in the study. by Ehsan Ghafouri (21688451)

“…<div><p>Climate change has emerged as a significant driver of biodiversity loss, with profound implications for species distribution. …”

Response Curves of environmental variables. by Ehsan Ghafouri (21688451)

“…<div><p>Climate change has emerged as a significant driver of biodiversity loss, with profound implications for species distribution. …”

Relative Variable Importance. by Ehsan Ghafouri (21688451)

“…<div><p>Climate change has emerged as a significant driver of biodiversity loss, with profound implications for species distribution. …”

Ablation results. by Gang Xu (219455)

“…Evaluation on the ScanNetV2 multi-view 3D object detection dataset demonstrates that ImVoxelGNet achieves a performance improvement of up to 2.2% in mean average precision (mAP). This improvement effectively demonstrates the efficacy of our method in significantly enhancing 3D object detection performance through improved geometric perception and comprehensive scene understanding. …”

Complexity comparison results. by Gang Xu (219455)

“…Evaluation on the ScanNetV2 multi-view 3D object detection dataset demonstrates that ImVoxelGNet achieves a performance improvement of up to 2.2% in mean average precision (mAP). This improvement effectively demonstrates the efficacy of our method in significantly enhancing 3D object detection performance through improved geometric perception and comprehensive scene understanding. …”

Ablation results on Nerf-Det [28]. by Gang Xu (219455)

“…Evaluation on the ScanNetV2 multi-view 3D object detection dataset demonstrates that ImVoxelGNet achieves a performance improvement of up to 2.2% in mean average precision (mAP). This improvement effectively demonstrates the efficacy of our method in significantly enhancing 3D object detection performance through improved geometric perception and comprehensive scene understanding. …”

Ablation results on noise. by Gang Xu (219455)

“…Evaluation on the ScanNetV2 multi-view 3D object detection dataset demonstrates that ImVoxelGNet achieves a performance improvement of up to 2.2% in mean average precision (mAP). This improvement effectively demonstrates the efficacy of our method in significantly enhancing 3D object detection performance through improved geometric perception and comprehensive scene understanding. …”

Figure 2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors by Constance A. Sobsey (19373550)

Data Sheet 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 4_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 1_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 5_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 2_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”

Table 3_Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel... by Zachary D. Wallen (19986522)

“…Introduction<p>Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. …”